ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022
Impact of travel burden on clinical outcomes in lung cancer.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Regional disparities in lung cancer surgery and survival in South Korea: a nationwide population-based retrospective cohort study using linked cancer registry and national health insurance data.Translational lung cancer research · 2026Article
- Traveling large distances for awake functional-based surgery of IDH-mutated grade 2 glioma: outcomes comparison between loco-regional versus international patients.Journal of neuro-oncology · 2026Article
- Article
- Social Vulnerability Index as a Tool to Evaluate the Distribution of Head and Neck Oncology Surgeons.The Laryngoscope · 2025Article
- Article
- Lung cancer-a one-way ticket.JNCI cancer spectrum · 2024Article
- Analysis of travel burden and travel support among patients treated at a comprehensive cancer center in the Southeastern United States.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Cancer Treatment Closer to the Patient Reduces Travel Burden, Time Toxicity, and Improves Patient Satisfaction, Results of 546 Consecutive Patients in a Northern Italian District.Medicina (Kaunas, Lithuania) · 2023Article
- Radiotherapy travel times - is time running out in India?Ecancermedicalscience · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOur study explores the influence of travel burden (measured as travel distance and travel time) on clinical outcomes in lung cancer patients.
methodsA retrospective analysis of a single Bulgarian center was performed. A total of 9240 lung cancer patients were included in the study. Travel distance and travel time between patients' city of residence and the treating facility were calculated with an online tool to determine the shortest route for travel using the existing road network. The probability of survival was estimated using the Kaplan-Meier method, and differences in survival in each subgroup were evaluated with a log-rank test.
resultsAbout one third of all included patients were living in the same city as the treating facility (n = 2746, 29.7%). Overall survival in our patient population was significantly lower with increasing travel distance (p < 0.001, Mantel-Cox log rank) and travel time (p < 0.001, Mantel-Cox log rank). The 1-year OS rate according to travel distance was 27.1% in the same city group, 22.4% in < 50-km group, and 20.5% in ≥ 50-km group (p < 0.001). The corresponding values for the 5-year OS rate were 2.9%, 2.6%, and 1.4% (p < 0.001).
conclusionIn this retrospective study, we discovered significant differences in the overall survival of patients with lung cancer depending on travel distance and travel time to the treating oncological facility. Despite having similar clinical and pathological characteristics (age, sex, stage at initial diagnosis, histologic subtype), the median overall survival was significantly lower in those subgroups of patients with a higher travel burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.